Search

everythinglearnresearchcommunity

for

Search:↓

RU58841 is a controversial hair loss treatment with mixed reviews; some users report success, often in combination with other treatments like finasteride or minoxidil, while others experience side effects like chest pain. The treatment's discontinuation is speculated to be due to patent expiration and lack of profitability, despite some users continuing to use it as part of a broader regimen.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

The conversation discusses the effectiveness of adding RCP (redensyl, capixyl, procapil) to a hair loss treatment regimen that includes minoxidil and finasteride. Users share experiences, suggesting RCP may not be as effective as minoxidil, but could be useful for creating topical solutions.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

Redensyl is being discussed as a potential substitute for minoxidil for hair growth after a brand switched from minoxidil to redensyl. The user is inquiring about the effectiveness of redensyl compared to minoxidil.

The drugs RU-58841, Pyrilutamide (KX-826), Apalutamide, Enzalutamide, and Darolutamide, which are nonsteroidal antiandrogens (NSAA), potentially impacting male fertility. Pyrilutamide, similar to Enzalutamide, may have reversible effects on fertility.

Teenagers experiencing hair loss face ridicule instead of support, impacting their mental health. Effective treatments mentioned include minoxidil, finasteride, and dermarolling.

The post discusses using a topical tincture containing zinc, azelaic acid, and other ingredients to inhibit 5 alpha-reductase activity for treating hair loss. The user plans to try this natural alternative before using finasteride or RU58841.

The conversation is about the effectiveness of Breezula for hair loss, with skepticism expressed due to lack of scientific proof and mixed results from those using Breezula and RU58841. Some are waiting for clinical trial results before trying treatments like Breezula and SM04554.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

The conversation is about comparing hair loss treatments Pyrilutamide (KX-826) and CB-03-01, discussing their cost, side effects, and effectiveness. The user questions whether to try CB-03-01, which is more expensive and potentially less effective, or switch to the cheaper and possibly better Pyrilutamide.

Hair loss treatments including Minoxidil, Finasteride and RU58841; with a focus on Pyrilutamide could potentially be used as an effective treatment.

The potential of using a specific antibody, HMI-115, as a treatment for hair loss alongside traditional treatments such as minoxidil and finasteride. The user suggests trying either a 240 mg or 30 mg dose to see if it works.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

CosmeRNA, a new hair loss treatment, is expected to release soon and may become part of the "big three" treatments alongside finasteride and minoxidil. It works differently from finasteride by targeting androgen receptors in hair follicles, potentially offering fewer side effects.

Redensyl, which is a topical alternative to Minoxidil for hair loss. It may have advantages such as not making the hair greasy and lasting longer after discontinuing use than minoxidil. There are some positive reports from users, but also some negative ones, so it's unclear how effective this treatment will be in comparison to Minoxidil and other treatments like Finasteride or RU58841.

Clascoterone, an acne treatment that blocks DHT, is being developed for scalp use against hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.

A potential treatment for alopecia involving a protein that calms hair follicles has shown promise in rats, but skepticism remains about its applicability to humans. Many users express doubt about the timeline for effective hair loss treatments, comparing it to past unfulfilled promises.

A 24-year-old with hair thinning is using a regimen including dutasteride, RU58841, HGH, GHK-cu, and other compounds to protect and regrow hair. They are also incorporating a mild cutting cycle with testosterone propionate, anavar, and tirzepatide.

Breezula offers modest hair growth similar to finasteride and is expected to be available by late 2026. It is a safe alternative without hormonal side effects and works well with minoxidil.

A user plans to undergo a temporary MtF transformation to regrow hair, using estrogen, RU58841, and Dutasteride, then revert with testosterone. Many users criticize the plan, suggesting alternatives like hair transplants, and emphasize that estrogen is not a reliable solution for hair regrowth.

Dutasteride may inhibit androgen receptors in addition to reducing DHT, potentially explaining its effectiveness over finasteride for hair loss. Concerns about its impact on muscle growth are debated, with some suggesting no significant effects.

The user is using Finasteride gel and considering adding Redensyl to their routine, along with weekly microneedling, but is hesitant to use Minoxidil due to its initial shedding phase. They seek advice on the safety and ideal routine for combining these treatments.

Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.

The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.

The conversation discusses the use of RU58841 for hair loss, with one user sharing a one-month difference in their hair after using it. Users discuss where to buy RU58841, potential side effects including heart issues, and mixed opinions on its effectiveness, with some questioning the need for treatment based on the before and after pictures.

User experienced hair regrowth after eliminating scalp itch with RU58841. Others discussed itch and hair loss connection, and effectiveness of combining RU58841 with 5AR inhibitors.

The user does not respond well to minoxidil and is seeking an alternative to Tretinoin to upregulate sulfurtransferase activity for hair loss treatment. No specific alternative treatments were mentioned.

Hair loss discussion mentions treatments Minoxidil, Finasteride, and RU58841. Verteporfin shows promise for scar/regrowth after 84 days.